Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

New Research May Impact Treatment of MS

August 20, 2010 7:56 am | News | Comments

The results of a new study conducted could have an impact on the treatment of multiple sclerosis and other autoimmune diseases, which affect tens of thousands of people.


Gilead Receives Paragraph IV Letter Over Hepsera

August 20, 2010 7:47 am | News | Comments

Gilead Sciences, Inc. announced receipt of a Paragraph IV Certification Notice Letter advising that Sigmapharm Laboratories, LLC submitted an Abbreviated New Drug Application (ANDA) to the FDA requesting permission to manufacture and market a generic version of Hepsera.


Protalex Begins Phase 1b RA Trial

August 20, 2010 7:35 am | News | Comments

Protalex, Inc.  announced the dosing of the first patient in a multicenter Phase 1b clinical study of PRTX-100 in adult patients with active rheumatoid arthritis.


Drug Stores Offering Early Flu Shots

August 20, 2010 7:29 am | News | Comments

Many drug stores are offering flu shots earlier than in past years in line with a federal recommendation that everyone older than six months be vaccinated this season.


Panel Votes In Favor of Cymbalta Pain Expansion

August 20, 2010 7:26 am | by Matthew Perrone | News | Comments

A group of federal health experts narrowly voted to expand approval of a best-selling antidepressant, though panelists disagreed over which types of pain the pill effectively treats.


3D Cell Culture

August 19, 2010 8:21 am | Product Releases | Comments

KIYATEC Inc. has launched the first in a series of KIYAKUBE 3D Cell Culture Plasticware. This technology platform provides a universal and cost effective method which enables three-dimensional cell culture.


Laser-Scanning Microplate Cytometer

August 19, 2010 8:16 am | Product Releases | Comments

Mirrorball from TTP Labtech is the first microplate cytometer to offer simultaneous laser scanning, enabling superior multiplexing and resulting in higher throughput single pass scanning.


Hydrogel Mountant

August 19, 2010 8:04 am | Product Releases | Comments

The thermo-reversible hydrogel mountant CyGEL from Biostatus Ltd. offers a new, simplified method for the micro-injection of zebrafish embryos.


Rat Model

August 19, 2010 7:55 am | Product Releases | Comments

Transposagen Biopharmaceuticals, Inc. has added 170 genetically modified rats and related biomaterials to its database of laboratory rats with a genetic modification that can mimic a human disease.


ClinTec Partners With Elephant Capital

August 19, 2010 7:40 am | News | Comments

ClinTec International, a global clinical research organisation (CRO) announces a financial and strategic partnership with Elephant Capital Plc., an AIM market listed private equity firm.


Immunomedics And GE Collaborate on F-18 Labeling

August 19, 2010 7:35 am | News | Comments

Immunomedics, Inc. and GE Healthcare announced that they have entered into a license and collaboration agreement for the evaluation of labeling technologies based on Immunomedics' patented F-18 peptide labeling method.


New Gene Extends Lifespan of Model Organism

August 19, 2010 7:29 am | News | Comments

A team of scientists has found that suppressing a newly discovered gene lengthens the lifespan of roundworms. The results offer promising early evidence that scientists may succeed at finding targets for drugs that someday could allow people to live longer, healthier lives.


Drug-Eluting Stents Improve Angioplasty Outcome

August 19, 2010 7:23 am | News | Comments

Researchers have determined that the use of drug-eluting stents improves the long-term clinical outcome for patients undergoing percutaneous coronary intervention, commonly known as angioplasty.


Clavis Recruiting For Phase 3 Leukemia Trial

August 19, 2010 6:39 am | News | Comments

Clavis Pharma, the Norwegian cancer drug development company, announces that it has recruited the first patient into its pivotal Phase 3 study assessing its lead product elacytarabine in patients with late-stage acute myeloid leukemia.


ImmunoGen Cancer Treatment Given Orphan Drug Status

August 19, 2010 6:27 am | News | Comments

ImmunoGen, Inc., a developer of antibody-based targeted anticancer products, announced that the FDA has granted orphan drug designation to lorvotuzumab mertansine when used for the treatment of small-cell lung cancer (SCLC).



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.